Compare GDRX & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDRX | KARD |
|---|---|---|
| Founded | 2011 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2020 | 2026 |
| Metric | GDRX | KARD |
|---|---|---|
| Price | $3.60 | $12.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | $3.95 | ★ $38.67 |
| AVG Volume (30 Days) | ★ 878.1K | 609.2K |
| Earning Date | 11-03-2026 | 11-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $796,853,000.00 | N/A |
| Revenue This Year | $0.20 | N/A |
| Revenue Next Year | $4.72 | $50.00 |
| P/E Ratio | $119.33 | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.77 | $12.23 |
| 52 Week High | $4.05 | $27.00 |
| Indicator | GDRX | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 60.70 | 35.12 |
| Support Level | $3.26 | $12.23 |
| Resistance Level | $3.89 | $15.93 |
| Average True Range (ATR) | 0.12 | 1.36 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 91.46 | 10.95 |
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.